Natco Pharma supports Columbia University's clinical trial of chloroquine phosphate

23 May 2020 Evaluate
Natco Pharma has reiterated its commitment in supporting a clinical trial to prevent symptomatic SARS-CoV-2 infections by donating Chloroquine Phosphate (CQ) Tablets through its marketing partner in the United States, Rising Pharmaceuticals, to a study conducted by Columbia University, New York.

After Natco's recent donation to a global clinical trial conducted by the CROWN (COVID-19 Research Outcomes Worldwide Network) Collaborative at the Washington University School of Medicine in St. Louis it has now committed to support the Phase 2 of a clinical trial at Columbia University. The trial aims to determine the effectiveness of CQ in preventing COVID-19 infection in healthcare workers with moderate to high risk of exposure to the virus.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

925.05 3.00 (0.33%)
17-Dec-2025 10:57 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1772.55
Dr. Reddys Lab 1269.10
Cipla 1491.50
Zydus Lifesciences 914.75
Lupin 2103.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×